Pharvaris N.V. (PHVS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $28.50: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin... Read more
Sell if holding. Engine safety override at $28.50: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.0/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 85d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Pharvaris N.V.
Latest news
- Citizens Maintains Market Outperform on Pharvaris, Lowers Price Target to $74 — benzinga May 13, 2026 positive
- Pharvaris Q1 EPS $(0.69) Beats $(0.77) Estimate — benzinga May 12, 2026 positive
- Pharvaris Prices Underwritten Offering Of 3,874,664 Shares At $29.68 Per Share — benzinga May 8, 2026 neutral
- Pharvaris Presents Data Evaluating Safety Margins Of Administration Of Deucrictibant IR Capsule In Combination With Deuc — benzinga Apr 20, 2026 positive
- Wolfe Research Initiates Coverage On Pharvaris with Outperform Rating, Announces Price Target of $42 — benzinga Apr 9, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $28.50: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $26.46. Score 5.0/10, moderate confidence.
Take-profit target: $40.38 (+41.9% upside). Prior stop was $26.46. Stop-loss: $26.46.
Quality below floor (1.5 < 4.0).
Pharvaris N.V. trades at a P/E of N/A (forward -10.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts cover PHVS with a consensus score of 4.3/5. Average price target: $46.
What does Pharvaris N.V. do?Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies...
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.